Skip NavigationSkip to Content

Exploiting embryonic niche conditions to grow Wilms tumor blastema in culture

  1. Author:
    Wojcik, Heather M
    Lovvorn, Harold N
    Hollingshead,Melinda
    Pierce, Janene
    Stotler,Howard
    Murphy, Andrew J
    Borgel,Suzanne
    Phelps, Hannah M
    Correa, Hernan
    Perantoni,Alan
  2. Author Address

    Cancer and Developmental Biology Laboratory, National Cancer Institute, Frederick, MD, United States. Department of Pediatric Surgery, Monroe Carell Jr. Children's Hospital at Vanderbilt University, Nashville, TN, United States. Biological Testing Branch/Developmental Therapeutics Program, National Cancer Institute, Frederick, MD, United States. Leidos Biomedical Research, National Cancer Institute at Frederick, Frederick, MD, United States. Division of Pediatric Pathology, Monroe Carell Jr. Children's Hospital at Vanderbilt University, Nashville, TN, United States.
    1. Year: 2023
    2. Date: Mar 16
    3. Epub Date: 2023 03 16
  1. Journal: Frontiers in Oncology
    1. 13
    2. Pages: 1091274
  2. Type of Article: Article
  3. Article Number: 1091274
  1. Abstract:

    Wilms Tumor (WT), or nephroblastoma, is the most common pediatric kidney cancer. Most WTs display a "favorable" triphasic histology, in which the tumor is comprised of blastemal, stromal, and epithelial cell types. Blastemal predominance after neoadjuvant chemotherapy or diffuse anaplasia ("unfavorable" histology; 5-8%) portend a worse prognosis. Blastema likely provide the putative cancer stem cells (CSCs), which retain molecular and histologic features characteristic of nephron progenitor cells (NPCs), within WTs. NPCs arise in the metanephric mesenchyme (MM) and populate the cap mesenchyme (CM) in the developing kidney. WT blastemal cells, like NPCs, similarly express markers, SIX2 and CITED1. Tumor xenotransplantation is currently the only dependable method to propagate tumor tissue for research or therapeutic screening, since efforts to culture tumors in vitro as monolayers have invariably failed. Therefore, a critical need exists to propagate WT stem cells rapidly and efficiently for high-throughput, real-time drug screening. Previously, our lab developed niche conditions that support the propagation of murine NPCs in culture. Applying similar conditions to WTs, we assessed our ability to maintain key NPC "stemness" markers, SIX2, NCAM, and YAP1, and CSC marker ALDHI in cells from five distinct untreated patient tumors. Accordingly, our culture conditions maintained the expression of these markers in cultured WT cells through multiple passages of rapidly dividing cells. These findings suggest that our culture conditions sustain the WT blastemal population, as previously shown for normal NPCs. As a result, we have developed new WT cell lines and a multi-passage in vitro model for studying the blastemal lineage/CSCs in WTs. Furthermore, this system supports growth of heterogeneous WT cells, upon which potential drug therapies could be tested for efficacy and resistance. Copyright © 2023 Wojcik, Lovvorn, Hollingshead, Pierce, Stotler, Murphy, Borgel, Phelps, Correa and Perantoni.

    See More

External Sources

  1. DOI: 10.3389/fonc.2023.1091274
  2. PMID: 37007076
  3. PMCID: PMC10061139

Library Notes

  1. Fiscal Year: FY2022-2023
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel